Stockopedia rates Editas Medicine Inc as a Adventurous Momentum Trap . 5 brokers rate it as a 'Buy'. Click to view NSQ:EDIT's StockReport. Their stock opened with $16.00 in its Feb 3, 2016 IPO. Stock Symbol NASDAQ: EDIT Valuation at IPO $571M Money Raised at IPO $94.4M IPO Share Price It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company Latest Editas Medicine Inc (EDIT:NSQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. 16 Feb 2017 The ruling affected the stock prices of CRISPR, Editas and Intellia. of investors in CRISPR Therapeutics and Intellia Therapeutics, biotechs
Find real-time EDIT - Editas Medicine Inc stock quotes, company profile, news and forecasts from CNN Business.
Nov 19, 2019 · CRISPR Therapeutics stock jumps on early gene editing data . trading around $67.92 as of 2:45 p.m. Vertex's stock price was up two percent. FDA clears Editas to test gene-editing drug in Editas Medicine | Crunchbase Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. Search Crunchbase. Advanced. Try Pro free Solutions. Products. Resources. Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. IPO & Stock Price . Editas Medicine is registered under EDIT - Editas Medicine Stock Price - Barchart.com 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Editas Medicine Market Cap 2015-2019 | EDIT | MacroTrends Editas Medicine market cap history and chart from 2015 to 2019. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding.
Editas Medicine, Inc. (EDIT) Stock Forum & Discussion ...
Stock Price Forecast. The 7 analysts offering 12-month price forecasts for Editas Medicine Inc have a median target of 33.00, with a high Earnings per Share The latest Editas Medicine Inc USD0.0001 share price. View recent trades and share price information for Editas Medicine Inc USD0.0001. Investing ideas, stock information, fundamental analysis, technical analysis on EDITAS MEDICINE INC ($EDIT) from Singapore's largest stock investing community. Previous Close 19.980. Buy Price 19.020. Buy Volume 12. Sell Price 19.570. Editas Medicine is a leading gene editing company focused on developing CRISPR medicines for people with serious diseases.
